On May 29th, Concord Biotech will convene a meeting to review their Q4 and full-year 2026 results, as well as consider the final dividend payout for shareholders and discuss other business-related topics.

Concord Biotech experienced a 1.84% drop in share prices, following Citi's reduction in target price due to concerns over projected revenues. This downgrade was largely attributed to increased competition in the API market for the upcoming fiscal year.

Concord Biotech's target price has been reduced to ₹1,190 by Citigroup due to expected earnings per share (EPS) reductions of around 20-23% for fiscal years 2026 and 2027. The revision is attributed to several factors such as slowdown in API production, margin compression, tariff difficulties, tender delays, and challenges with CDSCO approvals.

Concord Biotech recently completed a significant block deal worth INR 31.1 crore, with each of the approximately 290,728 shares trading at INR 1,070. This indicates strong investor interest in the biotech company.

Concord Biotech has purchased Celliimune Biotech for approximately $940,000 to strengthen its research efforts in the field of DNA engineering for cancer treatments. The move aims to accelerate advancements in cancer therapeutics.